Search Results for: "Clinic Roundup"
-
Clinic Roundup
TWi Biotechnology Inc., of Taipei, Taiwan, completed recruitment of 240 patients in its randomized, double-blind, placebo-controlled Phase IIb trial of AC-201 for Type II diabetesBioWorld Today | Thursday, September 8, 2011 -
Clinic Roundup
Jennerex will proceed to a Phase IIb trial in the same indication in patients who have failed sorafenib...Pharmasset Inc., of Princeton, N.J., reported sustained virologic response (SVR) results from its Phase IIb PROTON study of PSI-7977 dosed once-daily in combination with peginterferon alfa 2a and ribavirin in treatment-naïve hepatitis C virus genotype 1 patientsBioWorld Today | Wednesday, September 7, 2011 -
Clinic Roundup
Kuros Biosurgery AG, of Zurich, Switzerland, said it completed recruitment in a Phase IIb trial of KUR211 in diabetic foot ulcersBioWorld Today | Friday, September 2, 2011 -
Clinic Roundup
Ltd., of Melbourne, Australia, said it enrolled the first subjects in a Phase IIb study of DoOvo to treat head liceBioWorld Today | Thursday, September 1, 2011 -
Clinic Roundup
Pearl Therapeutics Inc., of Redwood City, Calif., reported data from a Phase IIb study of formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist, compared to placebo and Foradil Aerolizer (Novartis AG) in patients with moderate to severe chronic obstructive pulmonary diseaseBioWorld Today | Wednesday, August 31, 2011 -
Clinic Roundup
Lasmiditan has completed five clinical trials outside the U.S., with Phase IIb results showing that it reduced moderate or severe headache at baseline to mild or none in two hoursBioWorld Today | Friday, August 19, 2011 -
Clinic Roundup
Emergent BioSolutions Inc., of Rockville, Md., said a Phase IIb trial of tuberculosis vaccine MVA85A has been initiated in HIV patientsBioWorld Today | Friday, August 12, 2011 -
Clinic Roundup
Glenmark Pharmaceuticals Ltd., of Mumbai, India, initiated two Phase IIb dose-ranging trials of Revamilast (GRC 4039) for asthma and rheumatoid arthritisBioWorld Today | Thursday, August 11, 2011 -
Clinic Roundup
Action Pharma A/S, of Arhus, Denmark, said that it has completed the last visit of its last patient in a Phase IIb study of AP214 for prevention of kidney injury in patients undergoing cardiac surgeryBioWorld Today | Tuesday, August 9, 2011 -
Clinic Roundup
Healthpoint Biotherapeutics, of Fort Worth, Texas, an affiliate of DFB Pharmaceuticals Inc., reported positive topline results for its Phase IIb trial investigating the efficacy of HP802-247, an investigational allogeneic living cell suspension containing keratinocytes and fibroblasts, in venous leg ulcers...The primary objective of the study is to select, based on the anti-TNFalpha immune responses, the dose levels and dosing schedule to be tested in a subsequent Phase IIb studyBioWorld Today | Friday, August 5, 2011 -
Clinic Roundup
AB Science SA, of Paris, recruited the first patient in the Phase IIb/III study of masitinib in rheumatoid arthritis...Actelion Ltd., of Allschwil, Switzerland, reported that its selective S1P1 receptor agonist, ponesimod, met the primary endpoint – reduction in the number of new active inflammatory lesions in the brain – in a Phase IIb dose-finding study in patients with relapsing-remitting multiple sclerosisBioWorld Today | Thursday, August 4, 2011 -
Clinic Roundup
The firm filed for an SPA last year after interim results from the Phase IIb study showed a 50 percent to 60 percent increase in amputation-free survival. (See BioWorld Today, Oct. 21, 2010BioWorld Today | Wednesday, July 27, 2011 -
Clinic Roundup
Inotek Pharmaceuticals Corp., of Lexington, Mass., completed the first two of three stages of a multiple-dose Phase IIb trial of its eye drop candidate, INO-8875, in patients with glaucoma or ocular hypertensionBioWorld Today | Friday, July 22, 2011 -
Clinic Roundup
Pharmasset Inc., of Princeton, N.J., said that in a Phase IIb (PROTON) trial of its hepatitis C candidate, PSI-7977, 100 percent of subjects achieved a sustained virologic response, defined as HCV RNA below the limit of detection, 24 weeks after completion of the treatment...Synta Pharmaceuticals Corp., of Lexington, Mass., treated its first patient in a Phase IIb/III (GALAXY) trial of ganetespib in combination with docetaxel for non-small cell lung cancer (NSCLCBioWorld Today | Thursday, July 21, 2011 -
Clinic Roundup
Tobira recently launched a Phase IIb study of cenicriviroc in combination with Viread and Emtriva (emtricitabine, Gilead Sciences Inc.) in treatment-naïve HIV-infected patientsBioWorld Today | Wednesday, July 20, 2011 -
Clinic Roundup
Sanofi SA, of Paris, and Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., reported results from a Phase IIb (MOBILITY) trial of sarilumab in rheumatoid arthritis and ankylosing spondylitisBioWorld Today | Thursday, July 14, 2011 -
Clinic Roundup
RVX-208 is a small molecule that facilitates endogenous ApoA-I production A Phase IIb trial is ongoing...Zalicus Inc., of Cambridge, Mass., initiated a Phase IIb trial of Synavive (dipyridamole/ low-dose prednisolone) for rheumatoid arthritisBioWorld Today | Thursday, June 30, 2011 -
Clinic Roundup
Aastrom Biosciences Inc., of Ann Arbor, Mich., published interim data from its Phase IIb RESTORE-CLI trial of cell therapy ixmyelocel-T for critical limb ischemia in the Journal of Vascular SurgeryBioWorld Today | Monday, June 27, 2011 -
Clinic Roundup
Adeona Pharmaceuticals Inc., of Ann Arbor, Mich., said it is planning a multicenter, double-blind, placebo-controlled Phase IIb trial to evaluate the safety and efficacy of its AEN-100, a gastroretentive, sustained-release zinc-based tablet, and AEN-200, a copper tablet, for treatment of patients suffering from amyotrophic lateral sclerosis...Anacor Pharmaceuticals Inc., of Palo Alto, Calif., said partner GlaxoSmithKline plc, of London, initiated two separate Phase IIb trials of GSK 2251052BioWorld Today | Friday, June 24, 2011 -
Clinic Roundup
Rexahn Pharmaceuticals Inc., of Rockville, Md., completed enrollment in its Phase IIb trial of Serdaxin, a neuroprotective and antidepressant candidate, in major depressive disorder...Tobira Therapeutics Inc., of Manalapan, N.J., started a Phase IIb trial of CCR5/CCR2 inhibitor cenicriviroc (TBR-652) in a 48-week study in 150 HIV-1-infected, antiretroviral treatment-naïve patients with only CCR5-tropic virusBioWorld Today | Thursday, June 23, 2011
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.